-+ 0.00%
-+ 0.00%
-+ 0.00%

Dr Reddy’s taps Fresenius Kabi for exclusive US commercialization of rituximab biosimilar

PUBT·08/03/2026 10:25:23
Listen to the news
Dr Reddy’s taps Fresenius Kabi for exclusive US commercialization of rituximab biosimilar
  • Dr. Reddy’s signed a US commercialization agreement granting Fresenius Kabi exclusive rights to market its rituximab biosimilar.
  • The deal follows FDA clearance for the product, positioning Fresenius Kabi to lead the US launch while Dr. Reddy’s supplies from its Hyderabad biologics site.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000547), on August 03, 2026, and is solely responsible for the information contained therein.